CStone Pharmaceuticals announces its subsidiary, Giant Biologics, has received FDA approval for the Phase I clinical trial of SYS6037, a monkeypox mRNA vaccine. Developed with the Chinese Academy of Sciences, the vaccine shows promising preclinical results and aims to be a competitive market product, expanding the company's mRNA vaccine pipeline.
Summary generated by AI · Always verify with source document
Stock Code: 300765
Stock Abbreviation: CStone Pharma
Announcement No.: 2026-071
CStone Pharmaceuticals Co., Ltd.
Announcement on Phase I Clinical Trial Approval in the US for Subsidiary's SYS6037 Injection (Monkeypox mRNA Vaccine)
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
I. Overview
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.